Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZE94-0605 in Advanced Solid Tumors
NCT07524140Phase 1Recruiting
- Sponsor
- Eilean Therapeutics
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of ZE94-0605 in solid tumor (8 arms), sponsored by Eilean Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Maximally Tolerated Dose up to 24 months and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
ZE94-0605
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07524140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524140.